Back to top
more

Chemed (CHE)

(Delayed Data from NYSE)

$577.77 USD

577.77
99,595

-3.78 (-0.65%)

Updated Oct 7, 2024 04:00 PM ET

After-Market: $578.68 +0.91 (0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 10% (25 out of 252)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Wright Medical (WMGI) Beats on Q2 Earnings, Raises '18 View

Growth in the upper and lower extremity segments drives Wright Medical's (WMGI) Q2 results.

    Bio-Rad (BIO) Tops Earnings and Revenue Estimates in Q2

    Bio-Rad's (BIO) solid growth in North America, China and Asia Pacific reflects strong international foothold in Q2.

      CVS Health's (CVS) Q2 Earnings Beat Estimate, Margins Up

      CVS Health (CVS) reports strong Pharmacy Services revenues, benefiting from the upside in the specialty services. Year-over-year Retail/LTC comparisons are also encouraging.

        BioScrip (BIOS) Q2 Loss Wider Than Expected, Revenues Top

        A shift in BioScrip's (BIOS) strategy and the impact of implementing ASC 606 induce a Q2 earnings miss for the company. However, its progress with the new multi-faceted CORE plan is a positive.

          Penumbra (PEN) Q2 Earnings & Revenues Top Estimates, View Up

          Penumbra (PEN) benefits from strong growth across all geographies and product lines in Q2.

            Surmodics (SRDX) Beats Q3 Earnings Estimates, Raises '18 View

            Surmodics' (SRDX) third-quarter fiscal 2018 results benefit from increase in royalty and license fee revenues.

              Teleflex (TFX) Q2 Earnings Top, Sales Lag, '18 View Bearish

              Teleflex (TFX) rides high on a strong year-over-year revenue improvement, banking on balanced segmental growth and wide geographical expansion.

                Luminex (LMNX) Misses on Earnings in Q2, Margins Contract

                Luminex (LMNX) gains on ARIES and VERIGENE platforms in Q2; a solid guidance encourages.

                  Insulet (PODD) Q2 Loss Narrower Than Expected, Revenues Lag

                  We are encouraged by the year-over-year improvement in Insulet's (PODD) results on solid uptake of Omnipod system in the United States in Q2.

                    Henry Schein's (HSIC) Q2 Earnings Beat, '18 EPS View Up

                    All four of Henry Schein's (HSIC) operating segments recorded strong year-over-year growth in Q2.

                      Cardinal Health (CAH) Surpasses Earnings Estimates in Q4

                      Cardinal Health (CAH) witnesses strong Q4, owing to strong sales at Pharmaceutical and the Medical segments. It provides an impressive FY19 view.

                        Bruker (BRKR) Q2 Earnings Meet Estimates, Margins Expand

                        Bruker's (BRKR) strategic M&A activity is consistently raising investors' hopes. Further, the company's current focus on product development through higher R&D is an upside.

                          Quality Systems (QSII) Q1 Earnings & Revenues Beat Estimates

                          Quality Systems (QSII) gains from solid bookings in Q2; growing pipeline encourages.

                            Cerner (CERN) Beats Q2 Earnings Estimates, Bookings Rise Y/Y

                            Cerner (CERN) gains from solid bookings growth in Q2; developments in the EHR front are promising.

                              Genomic Health (GHDX) Q2 Earnings and Revenues Top Estimates

                              We are encouraged by the year-over-year rise in Genomic Health's (GHDX) revenues in Q2, driven by solid performances in the United States and internationally.

                                ResMed (RMD) Q4 Earnings & Sales Beat on Overall Growth

                                ResMed (RMD) sees solid contributions from domestic and international businesses in Q4.

                                  PRA Health's (PRAH) Q2 Earnings Top, Revenues Lag Estimates

                                  PRA Health (PRAH) sees year-over-year double-digit growth in earnings, revenues and net new business in Q2. However, increasing labor-related costs in the Clinical Research wing is a concern.

                                    PerkinElmer (PKI) Q2 Earnings & Revenues Top, EPS View Up

                                    Solid performance by PerkinElmer's (PKI) DAS and Diagnostics arms is a key positive in Q2. The company saw strength across all major geographies in Asia, Americas, Europe and the BRIC nations.

                                      IDEXX Laboratories (IDXX) Beats on Q2 Earnings, EPS View Up

                                      IDEXX Laboratories' (IDXX) stellar performance in Q2 was driven by strong sales at the CAG business.

                                        NuVasive (NUVA) Q2 Earnings Meet Estimates, EPS View Down

                                        NuVasive (NUVA) expects robust demand for recently-launched products and positive surgeon conversion efforts as its new Lateral Single-Position Surgery procedure gains traction in the market.

                                          Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Dips

                                          At the Home Health and Hospice divisions, Amedisys (AMED) gains traction from solid growth in Medicare and non-Medicare revenues.

                                            Hologic (HOLX) Beats Earnings and Revenue Estimates in Q3

                                            Solid growth at Hologic's (HOLX) Breast Health and international business drives top line in Q3.

                                              QIAGEN (QGEN) Beats Earnings and Revenue Estimates in Q2

                                              QIAGEN's (QGEN) year-over-year revenue growth in Q2 is encouraging. Expansion in operating margin buoys optimism.

                                                Illumina (ILMN) Beats on Q2 Earnings, Lifts '18 Guidance

                                                Illumina (ILMN) gains on strong consumables growth across its sequencing portfolio with strength in all throughput categories in Q2.

                                                  Cardiovascular Systems (CSII) Beats on Q4 Earnings & Revenues

                                                  Cardiovascular Systems (CSII) sees strength in Coronary device and peripheral device segments in Q4.